ZA200800246B - Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms - Google Patents

Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms

Info

Publication number
ZA200800246B
ZA200800246B ZA200800246A ZA200800246A ZA200800246B ZA 200800246 B ZA200800246 B ZA 200800246B ZA 200800246 A ZA200800246 A ZA 200800246A ZA 200800246 A ZA200800246 A ZA 200800246A ZA 200800246 B ZA200800246 B ZA 200800246B
Authority
ZA
South Africa
Prior art keywords
immunostimulant
neoplasms
treatment
immune system
oncolytic virus
Prior art date
Application number
ZA200800246A
Other languages
English (en)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of ZA200800246B publication Critical patent/ZA200800246B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200800246A 2005-08-31 2006-08-22 Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms ZA200800246B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71328705P 2005-08-31 2005-08-31

Publications (1)

Publication Number Publication Date
ZA200800246B true ZA200800246B (en) 2009-08-26

Family

ID=37808428

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800246A ZA200800246B (en) 2005-08-31 2006-08-22 Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms

Country Status (13)

Country Link
US (1) US20070071723A1 (zh)
EP (1) EP1922085A4 (zh)
JP (1) JP2009504687A (zh)
CN (1) CN101304761A (zh)
AR (1) AR056487A1 (zh)
AU (1) AU2006287052B2 (zh)
CA (2) CA2621127C (zh)
IL (1) IL188816A0 (zh)
MX (1) MX2008002743A (zh)
SG (1) SG149870A1 (zh)
TW (1) TW200812614A (zh)
WO (1) WO2007025365A1 (zh)
ZA (1) ZA200800246B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
GB0720624D0 (en) * 2007-10-20 2007-11-28 Academisch Ziekenhuis Leiden Viral Modification
WO2009135614A2 (en) * 2008-05-09 2009-11-12 Bayer Schering Pharma Aktiengesellschaft Use of a virus regimen for the treatment of diseases
US9707285B2 (en) 2009-03-16 2017-07-18 Turnstone Limited Partnership Vaccination methods
US20100297072A1 (en) * 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
CN103260650B (zh) * 2010-10-20 2015-05-06 西奈山医学院 使用髓源抑制细胞治疗肿瘤的方法和组合物
CN108125989A (zh) * 2011-04-12 2018-06-08 英特维特国际股份有限公司 溶瘤作用中的禽偏肺病毒
US10238698B2 (en) * 2012-01-25 2019-03-26 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
WO2013163724A1 (en) * 2012-04-30 2013-11-07 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
AU2014221143B2 (en) 2013-02-21 2019-02-07 Turnstone Limited Partnership Vaccine composition
SG11201607130RA (en) * 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
TW201632207A (zh) * 2015-01-16 2016-09-16 世代好公司 細胞穿透抗體
GB201504251D0 (en) 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CN108338994A (zh) 2017-01-25 2018-07-31 杭州康万达医药科技有限公司 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
WO2020227503A1 (en) * 2019-05-09 2020-11-12 Sator Therapeutics LLC Delivery of oncolytic viruses using dendritic cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113584A1 (en) * 2004-04-29 2005-12-01 Board Of Regents, University Of Texas System Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting

Also Published As

Publication number Publication date
US20070071723A1 (en) 2007-03-29
CN101304761A (zh) 2008-11-12
CA2621127A1 (en) 2007-03-08
IL188816A0 (en) 2008-08-07
TW200812614A (en) 2008-03-16
AU2006287052A1 (en) 2007-03-08
EP1922085A1 (en) 2008-05-21
SG149870A1 (en) 2009-02-27
EP1922085A4 (en) 2009-12-30
AU2006287052B2 (en) 2009-03-12
CA2621127C (en) 2014-02-25
CA2825762A1 (en) 2007-03-08
MX2008002743A (es) 2008-03-26
JP2009504687A (ja) 2009-02-05
AR056487A1 (es) 2007-10-10
WO2007025365A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
ZA200800246B (en) Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
GB0519124D0 (en) Virus scanner system and method with integrated spyware detection capabilities
EP2277049A4 (en) AUTOANTIBODIES IN THE DETECTION AND TREATMENT OF CANCER
IL193832A0 (en) Extracts and methods comprising ganoderma species
PL2059256T3 (pl) Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
IL200432A (en) Human antibodies against hepatitis C virus and their uses
IL197781A0 (en) Lyophilization methods and apparatuses
IL196694A0 (en) Iterative methods for dose reduction and image enhancement in tomography
EP2246064A4 (en) RECOMBINANT IMMUNOMODULATION PROTEIN (RLZ-8) FROM GANODERMA LUCIDIUM AND USES THEREOF
ZA200807394B (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
HK1245334A1 (zh) 改善的用於人乳頭狀瘤病毒的疫苗及其使用方法
ZA201105343B (en) Cyclosporine derivative for use in the treatment of hcv and hiv infection
IL211864A0 (en) Amino subtitiuted benzoyl derivatives, methods for their preparation and their use in the preparation of anti-virus drugs
EP2334701A4 (en) FULLY HUMAN ANTIBODIES AGAINST ANTIGENES ASSOCIATED WITH MELANOMA OF HIGH MOLECULAR WEIGHT AND USES THEREOF
HK1121350A1 (en) Permanent wave treatment method and device
IL229926A0 (en) 3neil peptides and vaccines containing them
ZA201201373B (en) Picrorhiza kurroa extract for prevention, elimination and treatment of dna based viruses humans and in biotech industry
EP2217573A4 (en) TREATMENT AND PREVENTION OF VIRUS INFECTIONS
EP1976348A4 (en) INDUCTION ACCELERATOR AND METHOD OF ACCELERATING ELECTRICALLY CHARGED PARTICLES
ZA200902533B (en) Methods for treating and reducing the incidence of Newcastle disease
GB2463584B (en) Carbohydrate-lipid constructs and their use in preventing or treating viral infection
GB0600081D0 (en) Chicken virus vaccine and diagnostic
EP1844675A4 (en) METHOD AND DEVICE FOR CONTINUOUS WAVING TREATMENT
EP2424898A4 (en) CONJUGATES OF GM-CSF AND INTERLEUKIN-21 AND USES THEREOF IN MODULATION OF IMMUNE RESPONSE AND TREATMENT OF CANCER
EP2091558A4 (en) METHOD FOR REINFORCING THE IMMUNE RESPONSE WITH ELECTROPORATION BASED VACCINATION AND BOOSTING